Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06996080 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
A Phase 3 study of Macular Edema Secondary to Inflammation, sponsored by Kodiak Sciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
- 20
- Study locations
NCT06996080 is a Phase 3 study of Macular Edema Secondary to Inflammation that is actively recruiting participants, run by Kodiak Sciences. The registered enrollment target is 150 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT06996080, a Phase 3 study of Macular Edema Secondary to Inflammation, is actively recruiting participants, sponsored by Kodiak Sciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)
Conditions Studied
Interventions
- OTHER Sham Comparator
- DRUG KSI-101
Study Locations (20)
California
- Global Research Management, Inc. - Glendale
- UCLA Stein Eye Institute - Los Angeles
- Stanford Byers Eye Institute - Palo Alto
- California Eye Specialists Medical Group, Inc. - Pasadena
- California Eye Specialists Medical Group, Inc. - Redlands
- Retina Consultants of Southern California - Redlands
- Retinal Consultants Medical Group Inc - Sacramento
North Carolina
- North Carolina Retina Associates (Cary) - Cary
- North Carolina Retina Associates (Wake Forest) - Wake Forest
Arizona
- Research Network Arizona - Scottsdale
Connecticut
- Retina Group of New England, PC - Waterford
Florida
- Retina Group of Florida (Ft. Lauderdale) - Fort Lauderdale
Indiana
- Associated Vitreoretinal and Uveitis Consultants LLC - Carmel
Maryland
- Cumberland Valley Retina Consultants - Hagerstown
Minnesota
- Retina Consultants of Minnesota - Saint Louis Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-07-16 |
| Est. Completion | 2027-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06996080
The ClinicalTrials.gov registry entry for NCT06996080 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kodiak Sciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Macular Edema Secondary to Inflammation appearing as the primary indexed condition, and to 2 interventions - of which Sham Comparator is the first listed.
NCT06996080 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, North Carolina, Arizona.
Frequently Asked Questions
What is clinical trial NCT06996080 about?
NCT06996080 is a clinical study titled "A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE". A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)
What is the current status of trial NCT06996080?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2025-07-16. Estimated completion is 2027-07.
What conditions does trial NCT06996080 study?
This clinical trial studies the following conditions: Macular Edema Secondary to Inflammation.
What interventions are being tested in trial NCT06996080?
The interventions under investigation include: Sham Comparator (OTHER), KSI-101 (DRUG).
Who is sponsoring clinical trial NCT06996080?
This trial is sponsored by Kodiak Sciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06996080 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Edema Secondary to Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.